CAS:1510829-06-7Vecabrutinib

您的位置 : 首页 / Protein Tyrosine Kinase/RTK / BTK / Vecabrutinib

Vecabrutinib Vecabrutinib Cat No. FB12110Cas No. 1510829-06-7

Synonyms: SNS-062

Vecabrutinib is a potent BTK inhibitor, with IC50s of 4.6 nM and 1.1 nM for WT BTK and C481S BTK, respectively, and also inhibits ITK activity (IC50, 24 nM).

规格	价格	促销价格	库存

18817579266

立即询价

咨询

18817579266

立即询价

实验数据

储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 1.8871 mL
- 9.4354 mL
- 18.8708 mL
- 5 mM
- 0.3774 mL
- 1.8871 mL
- 3.7742 mL
- 10 mM
- 0.1887 mL
- 0.9435 mL
- 1.8871 mL
计算器摩尔计算器总药量计算器工作液计算器

技术信息

CAS号

1510829-06-7

储存条件

粉末: -20°C 3 年

液体: -80°C 12 月

分子式

C22H24ClF4N7O2

运输

蓝冰

分子量

529.92

别名

SNS-062

溶解度

DMSO	120.0 mg/mL (226.5 mM) warming

动物实验配方

靶点数据

生物活性

描述Bruton's tyrosine kinase (BTK), a member of the Tec family of tyrosine kinases and expressed in B cells, macrophages, and monocytes but not in T cells, plays a crucial role in signaling through the B cell receptor (BCR) and the Fcγ receptor (FcγR) in B cells and myeloid cells, respectively. Vecabrutinib is a potent, noncovalent BTK and ITK (interleukin-2-inducible kinase) inhibitor, with K_d of 0.3 nM and 2.2 nM, respectively. It inhibits WT and C481S BTK with IC₅₀s of 2.9 nM and 4.4 nM, respectively. Vecabrutinib decreases viability of primary CLL cells in the presence of HS5 stromal protection by 5.5%. Vecabrutinib has good oral bioavailability in rat and dog (%F ≥ 40%) and a terminal half-life of 5 to 6 hours and is well tolerated with continuous drug levels.